Zydus Lifesciences stock
Price history
+29.31% over the period1 year: from ₹928.00 (November 20, 2025) to ₹1,200.00 (November 20, 2026), +29.31%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ₹1,200.00 |
| October 30, 2026 | ₹1,245.50 |
| September 30, 2026 | ₹1,162.00 |
| August 31, 2026 | ₹1,161.30 |
| July 31, 2026 | ₹1,126.80 |
| June 30, 2026 | ₹1,112.60 |
| May 29, 2026 | ₹1,077.70 |
| April 30, 2026 | ₹891.90 |
| March 30, 2026 | ₹871.20 |
| February 27, 2026 | ₹921.70 |
| January 30, 2026 | ₹885.30 |
| December 31, 2025 | ₹914.35 |
| November 28, 2025 | ₹942.50 |
| November 20, 2025 | ₹928.00 |
At a glance
The company
Research, develop, and market pharmaceutical products, generics, biosimilars, vaccines, medical devices and consumer wellness brands across India, US, Europe and internationally
Latest results
Quarter to September 30, 2026 · EPS ₹9.00 (estimate ₹8.39)
TickerLandia's take on Zydus Lifesciences
- Priced as usual relative to earnings: P/E on the latest fiscal year 24 vs a median of 21 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 29 vs 29 (+0%) in a group of 11.
- Strong point: Market momentum (84/100 in its group). Weak point: Dividend (29/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.26% from the 52-week high
Analysts · 29 analysts
Average target₹1,238.46+3.21% vs. price
Buy 15 · Hold 8 · Sell 6 · Hold
TickerLandia Fingerprint: Zydus Lifesciences
Compared with similar companies: very low risk and very strong momentum.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh62
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 18.3 65 Forward P/E 24.3 60 P/E (trailing 12 months) 28.7 56 Price/book 4.30 68 Price/sales 3.94 59 Profitabilityaverage53
How much it earns on revenue and capital.
Metric Value Position in group ROE 14.7% 58 ROA 6.4% 50 Gross margin 72.2% 65 Operating margin 17.2% 40 Net margin 13.8% 50 Earnings stabilityaverage50
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.1% 38 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +16.35% 83 Revenue growth (year over year) +29.20% 80 Earnings growth (year over year) −25.80% 30 Financial strengthlow39
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.46 39 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.43 55 Interest coverage 16.0 50 Current ratio 1.02 12 Dividendlow29
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 27 years 80 Dividend yield 0.1% 5 Payout ratio 2.4% 2 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +13.24% 88 1-year return +29.31% 79 Riskvery low11
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.3% 22 Maximum drawdown (12 months) 8.8% 0
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Zydus Lifesciences is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2026), Zydus Lifesciences's P/E today is 24.0, in line with the median of its last 10 fiscal years (21.0; between 15.9 and 30.4 from 2017 to 2026). Zydus Lifesciences's P/E (trailing 12 months): 28.7, in line with the median of a group of 11 similar companies (28.7).
Compared with 11 similar companies
| Metric | Zydus Lifesciences | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 28.7 | Middle | |
| Forward P/E | 24.3 | Middle | |
| Operating margin | 17.2% | Middle | |
| ROE | 14.7% | Middle | |
| Debt/equity | 0.46 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Zydus Lifesciences. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹79.1B
Latest quarter · Q3 2026
Net income
₹9.26B
Latest quarter · Q3 2026
Quarterly net margin
11.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹1.2T
- P/E
- 28.7
- EPS
- ₹41.88
- Volume
- 780.37K
- Daily trading
- €18.77M
- Dividend yield
- 0.08%
- Last ex-dividend on July 24, 2026
How Zydus Lifesciences is changing
All resultsRevenue grew 13.5% a year on average over the last 5 years
Operating margin rose from 16.6% to 21.5%
Less cash than profit: free cash flow equal to 45% of net income
Returns
Zydus Lifesciences returns with dividends
₹1,000 invested in Zydus Lifesciences 5 years ago, on November 22, 2021, would be worth ₹2,713 today with dividends reinvested: +171.28% in total, +22.12% per year. On price alone it would be ₹2,630 (+162.98%).
| Period | Zydus Lifesciences | ₹1,000 becomes |
|---|---|---|
| 1 month | +7.40% | ₹1,074 |
| 6 months | +15.29% | ₹1,153 |
| Year to date | +31.24% | ₹1,312 |
| 1 year | +29.43% | ₹1,294 |
| 3 years | +91.45% | ₹1,915 |
| 5 years | +171.28% | ₹2,713 |
| 10 years | +255.60% | ₹3,556 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Zydus Lifesciences: technical analysis
Zydus Lifesciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 7.8% below its all-time closing high (₹1,300.90, August 9, 2024).
- Trend
- Upward
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- +13.24%
Support and resistance
Price areas where Zydus Lifesciences has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₹1,202.97+0.25%3 touches, last on August 28, 2026
- Last price₹1,200.00
- Support₹1,120.63−6.61%3 touches, last on July 14, 2026
- Support₹1,094.33−8.81%8 touches, last on October 26, 2026
- Support₹1,051.35−12.39%2 touches, last on June 17, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 26.3%
- Largest fall in the last year
- −8.80%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Zydus Lifesciences: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Zydus Lifesciences has been May: +4.00% on average, positive in 17 years out of 27. The weakest has been January: −2.44% on average, positive in 9 years out of 26. November, the current month, has been positive in 13 years out of 26 (+0.90% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −2.44% | −1.80% | 9 of 26 |
| February | +3.10% | +1.49% | 13 of 26 |
| March | +1.88% | +1.21% | 17 of 26 |
| April | +3.23% | +2.34% | 16 of 26 |
| May | +4.00% | +4.70% | 17 of 27 |
| June | +3.79% | +2.47% | 17 of 27 |
| July | +3.18% | +1.28% | 15 of 27 |
| August | +1.19% | +0.60% | 14 of 27 |
| September | +1.44% | +1.52% | 16 of 27 |
| October | +1.00% | +1.90% | 15 of 27 |
| November | +0.90% | +0.02% | 13 of 26 |
| December | +3.49% | +3.08% | 20 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Zydus Lifesciences and its competitors
Glucon D, Complan, Nycil, Everyuth, Nutralite and RiteBite Max Protein are among the consumer brands through which Zydus Lifesciences sells products in India and abroad, alongside a pharmaceutical business that covers active pharmaceutical ingredients, generics, branded generics, specialty formulations, biosimilars and vaccines. The company also develops biological products for oncology, autoimmune disorders, nephrology, rheumatology, hepatology and infectious diseases, and runs clinical trials for new chemical entities, biologics and vaccines.
- Headquarters
- Ahmedabad, India
- Employees
- 29,980
- Founded
- 1952
- Chief executive
- Sharvil Patel
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Zydus LifesciencesZYDUSLIFE | $12.92B | 17.2% | 28.7 | +15.29% |
| CiplaCIPLA | $12.34B | 13.0% | 39.5 | +1.11% |
| Zhejiang NHU002001 | $11.61B | 33.8% | 10.6 | −19.16% |
| Laurus LabsLAURUSLABS | $14.13B | 24.1% | 97.8 | +68.58% |
| Yunnan Baiyao Group000538 | $15.07B | 11.2% | 19.4 | +11.07% |
| PharmaEssentia6446 | $15.94B | 38.4% | 74.1 | +54.65% |
Same industry or related industries, similar size. Compare Zydus Lifesciences with its competitors · Full profile
